Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1200/JCO.2014.56.3379 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Fabrication of impedimetric sensor based on metallic nanoparticle for the determination of mesna anticancer drug.
Sci Rep
July 2023
Faculty of Chemistry, Bu-Ali Sina University, Hamedan, 6517838695, Iran.
Electrochemical impedance spectroscopy (EIS) is a highly effective technique for studying the surface of electrodes in great detail. EIS-based electrochemical sensors have been widely reported, which measure the charge transfer resistance (R) of redox probes on electrode surfaces to monitor the binding of target molecules. One of the protective drugs against hemorrhagic cystitis caused by oxazaphosphorine chemotherapy drugs such as ifosfamide, cyclophosphamide and trophosphamide is Mesna (sodium salt of 2-mercaptoethanesulfonate).
View Article and Find Full Text PDFAn in vitro cytotoxicity of glufosfamide in HepG2 cells relative to its nonconjugated counterpart.
J Egypt Natl Canc Inst
August 2021
Department of Pharmacology and Toxicology, Faculty of Pharmacy Ahram Canadian University, Giza, 267119, Egypt.
Background: Glufosfamide (β-D-glucosylisophosphoramide mustard, GLU) is an alkylating cytotoxic agent in which ifosforamide mustard (IPM) is glycosidically linked to the β-D-glucose molecule. GLU exerted its cytotoxic effect as a targeted chemotherapy. Although, its cytotoxic efficacy in a number of cell lines, there were no experimental or clinical data available on the oncolytic effect of oxazaphosphorine drugs in hepatocellular carcinoma.
View Article and Find Full Text PDFOxazaphosphorines combined with immune checkpoint blockers: dose-dependent tuning between immune and cytotoxic effects.
J Immunother Cancer
August 2020
Molecular Radiotherapy and Innovative Therapeutics, Unité Mixte de Recherche 1030 INSERM, Gustave Roussy, F-94805, Villejuif, France
Background: Oxazaphosphorines (cyclophosphamide (CPA), ifosfamide (IFO)) are major alkylating agents of polychemotherapy protocols but limiting their toxicity and increasing their efficacy could be of major interest. Oxazaphosphorines are prodrugs that require an activation by cytochrome P450 (CYP). CPA is mainly metabolized (>80%) to phosphoramide mustard while only 10%-50% of IFO is transformed in the alkylating entity, isophosphoramide mustard and 50%-90% of IFO release chloroacetaldehyde, a nephrotoxic and neurotoxic metabolite.
View Article and Find Full Text PDFPanax ginseng is superior to vitamin E as a hepatoprotector against cyclophosphamide-induced liver damage.
Complement Ther Med
October 2019
Department of Histology and Cytology, Faculty of Veterinary Medicine, Zagazig University, 44519, Zagazig, Egypt.
Background And Aims: Cyclophosphamide (CPh) is a frequently used drug, in human and animals for its immunosuppressive and anticancer potential. However, it is metabolized by the liver yielding damaging toxicants (to the liver itself and other non-target vital organs) via oxidative stress, apoptosis induction and finally necrosis. Since there is no escaping of using such harmful medications, we focused on alleviating its side-effects.
View Article and Find Full Text PDFTrofosfamide in the treatment of elderly or frail patients with diffuse large B-cell lymphoma.
J Cancer Res Clin Oncol
January 2019
Department of Haematology and Oncology, University Hospital of Schleswig-Holstein (UKSH), Ratzeburger Allee 160, 23538, Lübeck, Germany.
Purpose: The introduction of immunochemotherapy has led to a significant improvement in treatment results and prognosis of diffuse large B-cell non-Hodgkins lymphoma (DLBCL) both at initial diagnosis and in relapse. Trofosfamide, an oxazaphosphorine derivative, has been utilized as alternative treatment option for patients with lymphoproliferative diseases unsuitable for conventional chemotherapy agents and protocols because of age, comorbidity, or poor performance score. While data on the activity and safety of single-agent trofosfamide have been published, the potential value of this agent in immunochemotherapy in combination with anti-CD20 antibodies such as rituximab has not been investigated to our knowledge.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!